_edited.jpg)
GALEAS® Bladder
£699.00
£499.00
Nonacus - GALEAS® Bladder-
A comprehensive, laboratory developed, genetic test for identifying all
stages of bladder cancer from a urine sample
• Allows patients to provide a sample in the comfort of their own home. No hospital visits, no painful
procedure.
• Offers equivalent sensitivity and specificity to cystoscopy
• Reduces the number of unnecessary cystoscopies reducing costs and resource burden on clinics.
• Leverages targeted next generation sequencing chemistry to detect 451 mutations associated with
bladder cancer.
Why is testing for bladder cancer important?
Around 600,000 people worldwide are diagnosed annually with bladder cancer, and over 200,000 deaths are linked to the disease, making it the 10th most common cancer type in the western world.1
However, when diagnosed early, over 90% of patients with bladder cancer will survive 5 years, compared to only 36% of those with a late diagnosis.
Bladder cancer causes >5K deaths in the UK each year BUT
early detection can significantly impact survival
Haematuria - I confirm I have visible or non visible blood in my urine
Gender
Quantity
Biomarkers checked
Genes tested:
AKT1, ERBB2, NRAS,BRAF, ERBB3 ,PIK3CA
C3orf70, ERCC2, RHOB
CDKN1A, FBXW7, RXRA
CDKN2A, FGFR3, SF3B1
CREBBP, HRAS, TERT (promoter)
CTNNB1, KDM6A, TP53
ELF3, KRAS
Further information regarding these genes can be found here
Biomarkers were identified by Prof Rik Bryan and Dr Doug Ward at Birmingham
University, UK.
• NGS sequencing panel that targets promoter and exonic regions of 23 of the
most relevant genes associated with bladder cancer
• Identified by a combination of publicly available data and deep exome
sequencing
• Exome studies were performed on Caucasian populations
• 451 somatic mutations present in the panel have been shown to detect 96%
of bladder cancers in over 644 clinical samples.
Collection method
Urine Sample
When is GALEAS® Bladder testing used?
Why is testing for bladder cancer important?
Around 600,000 people worldwide are diagnosed annually with bladder cancer, and over 200,000 deaths are linked to the disease, making it the 10th most common cancer type in the western world.1
However, when diagnosed early, over 90% of patients with bladder cancer will survive 5 years, compared to only 36% of those with a late diagnosis.
When is bladder cancer testing used?
Blood in the urine (haematuria) is one of the most common signs of bladder cancer, and patients with this indication are primarily investigated by cystoscopy, which is uncomfortable, invasive, and an expensive procedure.
To overcome these challenges, the Informed Genomics bladder cancer test requires a simple, non-invasive urine sample and delivers results equivalent to that of cystoscopy for all stages of bladder cancer, including both NMIBC and MIBC.
Laboratory processing time
14days
(and 2 days transport via post)
How does it work?
1. Order Nonacus - GALEAS® Bladder
2. Receive the kit
3. Fill in order forms
4. Produce a Urine sample
5. Post sample kit to a Post Box
6. Results via password protected email and discussion of abnormal results with your own and recommended management plan made
7. Abdnormal results will be followed by a GP and a referral to a Urologist by our partner Private GP services at Pallmall Medical
Accreditations
Nonacus/Informed Genomics manufactures and processes Nonacus - GALEAS® Bladder and offers an efficient and effective, quality-driven service which ensures the high performance of our hereditary cancer testing service. This is underpinned by a strong and robust Quality Management System accredited to UKAS ISO 15189:2012
GALEAS® Bladder is distributed in the UK by Biox Medical Ltd